SVA Life Sciences is pleased to announce that Consultant Elena Pueraro has co-authored a manuscript published by Hugel America, Inc. in Dermatologic Surgery, a peer-reviewed journal covering relevant dermatology research for practitioners.
The topic of the manuscript is LetibotulinumtoxinA (consumer name: Letybo), an injectable to lessen the appearance of facial wrinkles known as glabellar (frown) lines. LetibotulinumtoxinA is manufactured in South Korea by parent company Hugel, Inc. and is marketed in more than 50 countries worldwide.
The manuscript shares pooled analyses from three separate phase three clinical trials sponsored by Hugel, and includes efficacy, safety, and patient-reported outcomes of the drug. Publications allow practitioners and key opinion leaders in the dermatology field to become educated on the drug.
The manuscript is the result of more than a year of hard work and coordination with various parties and is just one of the ways SVA Life Sciences can help biotechnology companies on their journey to FDA approval. Learn more about SVA and the services we offer.
For more information on Letybo, view the manuscript abstract.
